Abstract
Treatment of systemic vasculitides is usually based on the use of corticosteroids and other immunosuppressive drugs. We describe a 10-year-old girl with systemic vasculitis resistant to immunosuppressive treatment who had a rapid and impressive response to treatment with infliximab.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Petty RE, Cassidy JT (2000) Vasculitis and its classification. In: Cassidy JT and Petty RE (eds) Textbook of Pediatric Rheumatology. WB Saunders Company, pp 564–603
Ozen S, Besbas N, Saatci U, Bakkaloglu A (1992) Diagnostic criteria for polyarteritis nodosa in childhood. J Pediatr 2:206–209
Ozen S (2002) The spectrum of vasculitis in children. Best Pract Res Clin Rheumatol 16:411–425
Ozen S, Anton J, Arisoy N, Bakkaloglu A, Besbas N, Brogan P, et al. (2004) Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr 145:517–522
Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C, Guillevin L (2002) Efficacy of the anti-TNF-α antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology 41:1126–1132
Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe S, Probert L, et al. (1995) The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and lethality in vivo. Cytokine 7:15–25
Coutinho HM, Groothoff JW, Offringa M, Gruppen MP, Heymans HS (2001) De novo malignancy after paediatric renal replacement therapy. Arch Dis Child 85:478–483
Huong du L, Amoura Z, Duhaut P, Sbai A, Costedoat N, Wechsler B, Piette JC (2002) Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol 29:2571–2576
Lipsky PE, Van Der Heijde DMFM, William St. Clair E, Furst DE, Breedveld FC, Kalden JR, et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343:1594–1602
Rutgeerts P, D’Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn′s disease. Gastroenterology 117:761–769
Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, et al. (2004) Prospective study of TNFα blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 15:717–721
Saulsbury FT, Mann JA (2003) Treatment with infliximab for a child with Behçet’s disease. Arthritis Rheum 49:599–600
Weiss JE, Eberhard BA, Chowdhury D, Gottlieb B (2004) Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 31:808–810
Lahdenne P, Vähäsalo, Honkanen V (2003) Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 62:245–247
Antoni C, Braun J (2002) Side effects of anti-TNF therapy: Current knowledge. Clin Exp Rheumatol 20:s152–s157
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
de Kort, S.W.K., van Rossum, M.A.J. & ten Cate, R. Infliximab in a child with therapy-resistant systemic vasculitis. Clin Rheumatol 25, 769–771 (2006). https://doi.org/10.1007/s10067-005-0071-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-005-0071-7